Cargando…
Resveratrol-Mediated Reversal of Doxorubicin-Induced Osteoclast Differentiation
Secondary osteoporosis has been associated with cancer patients undertaking Doxorubicin (DOX) chemotherapy. However, the molecular mechanisms behind DOX-induced bone loss have not been elucidated. Molecules that can protect against the adverse effects of DOX are still a challenge in chemotherapeutic...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738652/ https://www.ncbi.nlm.nih.gov/pubmed/36499492 http://dx.doi.org/10.3390/ijms232315160 |